Search for: "Eli, Inc."
Results 801 - 820
of 999
Sort by Relevance
|
Sort by Date
10 Nov 2009, 9:59 pm
Eli Lilly & Co., which is scheduled for December 7th. [read post]
9 Nov 2009, 6:01 am
By David Evans Nov. 9 (Bloomberg) -- Prosecutor Michael Loucks remembers clearly when lawyers for Pfizer Inc., the world's largest drug company, looked across the table and promised it wouldn't break the law again. [read post]
5 Nov 2009, 7:20 pm
The FDA reported Byetta (exenatide), a drug manufactured by Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, prescribed to treat type 2 diabetes may pose serious kidney problems to patients. [read post]
5 Nov 2009, 1:12 pm
Diabetes Health Magazine recently published a study conducted by researchers from Medco Health Solutions, Inc., that says, "Type 2 diabetes patients who take Byetta run no greater risk of developing pancreatitis than patients with type 2 diabetes who do not take the drug. [read post]
4 Nov 2009, 4:33 am
Diversity Insight Daily Developments in EEO Law by Paul Mollica EBG Trade Secrets & Noncompete Blog ELI, Inc. [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
3 Nov 2009, 2:35 pm
On November 2, 2009 Amylin Pharmaceuticals, Inc., and Eli Lilly and Company issued their joint statement in response to the FDA on BYETTA® (exenatide) injection. [read post]
2 Nov 2009, 11:04 pm
Amylin Pharmaceuticals Inc. and Eli Lilly & Co. said safety warnings were strengthened for their diabetes drug Byetta relating to the risks of pancreatitis and the medicine's use by patients with severe kidney disease. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
18 Oct 2009, 9:17 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. [read post]
8 Oct 2009, 6:05 am
Teva Pharmaceuticals USA, Inc (Patent Docs) (Patent Baristas) (GenericsWeb) Trileptal (Oxacarbazepine) - Israel Patent Office prevents Novartis from submitting empirical evidence in patent opposition case (IP Factor) Vesicare (Solifenacin) – US: Astellas files patent infringement lawsuit against Teva over generic Vesicare (GenericsWeb) Zyprexa (Olanzapine) – Canada: Teva Novopharm invalidates Eli Lilly’s Canadian patent for Olanzapine (IP Factor)… [read post]
21 Sep 2009, 2:30 am
Patent holder Eli Lilly and Company has claimed infringement by Sandoz, Inc. and others. [read post]
19 Sep 2009, 9:54 am
Pfizer Inc., 1:07-cv-11428, U.S. [read post]
15 Sep 2009, 3:09 am
In Elie v. [read post]
8 Sep 2009, 4:00 am
Earlier this year, Indianapolis-based Eli Lilly & Co. agreed to pay $1.42 billion to settle a case over the marketing of its top seller, Zyprexa, an anti-psychotic drug. [read post]
2 Sep 2009, 5:57 pm
: Jacobson v Celgene (Patent Baristas) Ultracet (Tramadol/Acetaminophen) – US: CAFC vacates Ultracet obviousness decision: Ortho-McNeil Pharmaceutical, Inc v Teva Pharmaceuticals (not precedential) (Patently-O) (Patent Docs) (SmartBrief) Viread (Tenofovir) – India: MSF announces Patent Office rejected patents on AIDS drugs Tenofovir and Darunavir (Intellectual Property Watch) [read post]
2 Sep 2009, 8:04 am
Pfizer Inc agreed to plead guilty to a U.S. criminal charge relating to promotion of its now-withdrawn Bextra pain medicine and will pay a record $2.3 billion to settle allegations it improperly marketed 13 medicines. [read post]
